These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
817 related articles for article (PubMed ID: 35081305)
1. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications. Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305 [TBL] [Abstract][Full Text] [Related]
2. JAK-inhibitors in dermatology: current evidence and future applications. Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838 [TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology. Cinats A; Heck E; Robertson L Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037 [TBL] [Abstract][Full Text] [Related]
4. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. Klein B; Treudler R; Simon JC J Dtsch Dermatol Ges; 2022 Jan; 20(1):19-24. PubMed ID: 34962052 [TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review. Muddebihal A; Khurana A; Sardana K Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306 [TBL] [Abstract][Full Text] [Related]
6. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126 [TBL] [Abstract][Full Text] [Related]
7. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. Huang MY; Armstrong AW Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699 [TBL] [Abstract][Full Text] [Related]
8. Utilization of Topical Ruxolitinib in Dermatology: A Review. Kashetsky N; Turchin I Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609 [TBL] [Abstract][Full Text] [Related]
9. Topical Janus kinase inhibitors: A review of applications in dermatology. Hosking AM; Juhasz M; Mesinkovska NA J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776 [TBL] [Abstract][Full Text] [Related]
11. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Samuel C; Cornman H; Kambala A; Kwatra SG Dermatol Ther (Heidelb); 2023 Mar; 13(3):729-749. PubMed ID: 36790724 [TBL] [Abstract][Full Text] [Related]
12. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo. Niu C; Xie H; Aisa HA Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765 [TBL] [Abstract][Full Text] [Related]
13. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors. Svoboda SA; Johnson N; Phillips M Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108 [TBL] [Abstract][Full Text] [Related]
14. JAK-STAT pathway inhibitors in dermatology. Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920 [TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors in dermatology: The promise of a new drug class. Damsky W; King BA J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263 [TBL] [Abstract][Full Text] [Related]
16. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review. Dogra S; Sharma A; Mehta H; Sarkar R Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767 [TBL] [Abstract][Full Text] [Related]
18. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Roskoski R Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738 [TBL] [Abstract][Full Text] [Related]
19. Application of Baricitinib in Dermatology. Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989 [TBL] [Abstract][Full Text] [Related]
20. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety. Elmariah SB; Smith JS; Merola JF Am J Clin Dermatol; 2022 Jul; 23(4):427-431. PubMed ID: 35679017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]